News summarySEC EDGAROct 30, 2026, 12:00 PM
Regeneron Pharmaceuticals, 8-K (2.02, 9.01): reported results of operations
Regeneron reported third-quarter 2026 revenue of $5.116 billion, up 36%, and diluted GAAP and non-GAAP EPS of $18.45 and $20.07, respectively; it also expanded its Sanofi collaboration and said Pasatru was FDA-approved for FOP.